Simbec Research News Today

Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) rose 6% following the successful completion of the phase I study for its lead...

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) (OCT) hailed as a "major milestone" the successful completion of dosing for all cohorts...

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has successfully administered the final dose of its lead drug candidate, OCT461201, as...

/PRNewswire/ -- DelveInsights Menopause Market Insights report includes a comprehensive understanding of current treatment practices, menopause emerging...

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) (OCTP) said it has commenced its phase I clinical trial for the lead drug candidate,...

A cannabinoid receptor, that has shown potential as an effective treatment for chemotherapy induced peripheral neuropathy (CIPN) has been given approval for a phase 1 clinical trial by the Medicines and Healthcare Products Regulatory Agency (MRHA) and The Wales Research Ethics Committee 2 (REC 2).

Investegate announcements from Oxford Cannabinoid, 2022 Final Results

BioPharma

BBC News Published media captionA look back at Prince Philips legacy in Wales Whenever the Duke of Edinburgh visited Wales with the Queen, protocol dictated that he walk two paces behind her. To the crowds that lined the streets to greet them, this practice perfectly demonstrated his steadfast duty as royal consort. But it also belied the work he did in Wales independently of the monarch. It was on his wedding day in 1947 that the duality of his role in Wales was made official. That day, his fa...